INKT today
$9.53-$0.84 (-8.10%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourDescending Triangle
1 hourDescending Triangle
15 minStrong Bearish
5 minConsolidating
Daily trend turns down below $4.56
Key levels
Resistance$10.80
Resistance$10.04
Support$9.19
Support$8.38
Latest news & SEC filings
SEC FilingMiNK Therapeutics, Inc. filed a report on a major company event (Form 8-K)
EarningsMiNK Therapeutics Posts Q3 2026 Financial Results
All INKT news →About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company creating off-the-shelf cell therapies derived from donor iNKT cells, a type of immune cell, to treat tumors and immune-related disorders. Its most advanced therapy, agenT-797, is being studied in solid tumors, severe lung conditions such as acute respiratory failure, and complications after stem cell transplants. The company also develops engineered iNKT programs, including the CAR-iNKT candidates MiNK-413 and MiNK-215, and makes its cell products at its own site in Lexington, Massachusetts.
Based on the company's 10-K filed Mar 31, 2026.
Nasdaq · Healthcare
MiNK Therapeutics, Inc. (INKT)
What Is the Price Target for INKT?
SEPT Low Target
$38.00
SEPT Mid Target
$38.00
SEPT High Target
$38.00
Analyst Consensus
$38.00
Is INKT a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for INKT.
Start Free Trial →Is INKT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$38.00
17
Moat Score
NONE
3/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with INKT?
Insider Signal
SELLING
0 buys / 7 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Buell Jennifer | director officer | Sale | 6,938 | $73K | Oct 12, 2026 |
| Buell Jennifer | director officer | Buy | 23,191 | - | Oct 11, 2026 |
| Ryan Barbara | director | Buy | 1,622 | $18K | Sep 1, 2026 |
| Corvese Brian | director | Buy | 1,633 | $18K | Sep 1, 2026 |
| WIINBERG ULF | director | Buy | 1,279 | $14K | Sep 1, 2026 |
| Holcomb John Bradley | director | Buy | 1,233 | $14K | Sep 1, 2026 |
| Behner Peter | director | Buy | 1,485 | $16K | Sep 1, 2026 |
| Ryan Barbara | director | Sale | 500 | $6K | Jun 4, 2026 |
| Ryan Barbara | director | Sale | 1,000 | $13K | Jun 4, 2026 |
| Holcomb John Bradley | director | Buy | 1,091 | $14K | Jun 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →INKT Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-2.45%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for INKT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for INKT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:43:42 | $10.29 | 2,500 | $$26K | BUY |
| 19:05:04 | $10.48 | 1,337 | $$14K | SELL |
| 20:17:18 | $10.76 | 1,000 | $$11K | BUY |
| 19:42:07 | $11.04 | 2,000 | $$22K | MIDPOINT |
| 15:11:27 | $10.71 | 1,000 | $$11K | SELL |
5 dark pool trades shown · $$83K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for MiNK Therapeutics, Inc. (INKT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →INKT — frequently asked questions
What is INKT stock price today?
MiNK Therapeutics, Inc. (INKT) is at $9.53, down 8.10% (-$0.84) at the Nov 12, 2026 close.
Why is INKT stock down today?
Nov 11, 2026: MiNK Therapeutics reported its third-quarter 2026 results on an earnings call, with the quarterly loss coming in at 50 cents per share, narrower than the 66 cents analysts had projected. Despite the better-than-expected bottom line, INKT shares fell 2.72% to close at $10.22, trading between a low of $10.02 and a high of $10.88 on volume of 14,692.
What is the INKT price target?
The average analyst price target for INKT is $38.00, ranging from $38 to $38, based on 1 analysts.
What do analysts rate INKT?
Analyst ratings for INKT: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did INKT beat earnings?
INKT last reported on Aug 13, 2026: EPS -$0.62 vs -$0.60 expected — a miss of 3.3%.
Does INKT pay a dividend?
INKT does not currently pay a dividend.
What are INKT support and resistance levels?
Support: $9.19, $8.38, $6.80. Resistance: $10.04, $10.80, $11.68.
What are insiders doing with INKT?
Insider activity: SELLING, 0 buys and 7 sells in the last 90 days.
What is the latest news on INKT?
Nov 12, 2026: MiNK Therapeutics, Inc. filed a report on a major company event (Form 8-K) · Nov 12, 2026: MiNK Therapeutics Posts Q3 2026 Financial Results